Description
Atopaxar is a Protease-activated receptor-1 (PAR-1) inhibitor. It can inhibit the binding of a high-affinity thrombin receptor-activating peptide ([(3)H]haTRAP) to PAR-1 with IC50 value of 0.019µM. Atopaxar exhibits potent inhibitory effects on human platelet aggregation induced by thrombin and TRAP with IC50 values of 0.064 and 0.031µM. It may become a therapeutic option for atherothrombotic disease. In May 2012, Phase-II for Acute coronary syndromes in European Union was discontinued